AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25679067 — intervention group
Group type: COMPARATOR
Intervention: T (TH-302)
Number of subjects: 4
Study 25679067 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (V)
Number of subjects: 4
Study 25679107 — intervention group
Group type: EXPERIMENTAL
Intervention: Early peripheral perfusion-guided fluid therapy
Number of subjects: 0
Study 25679107 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25679125 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment for 6 months
Number of subjects: 589
Study 25679358 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-degree OASI (type 3a and 3b)
Number of subjects: 343
Study 25679358 — intervention group
Group type: COMPARATOR
Intervention: Fourth-degree OASI
Number of subjects: 343
Study 25679914 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory brainstem response using brainstem audiometry
Number of subjects: 48
Study 25679914 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 48
Study 25679979 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hand washing with soap
Number of subjects: 3045
Study 25679979 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved sanitation facilities
Number of subjects: 3045
Study 25679979 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-primary education of mothers
Number of subjects: 3045
Study 25679979 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition in children from impoverished households
Number of subjects: 3045
Study 25679979 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal variation (winter vs summer)
Number of subjects: 3045
Study 25680307 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMRI Pacemaker System
Number of subjects: 272
Study 25680594 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) plus cetuximab (400 mg/m² on day -7 and then 250 mg/m² on days 0 and +8)
Number of subjects: 50
Study 25680594 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) plus cetuximab
Number of subjects: 50
Study 25681380 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline resistance (4.2% in subcohort, 7.1% overall)
Number of subjects: 466
Study 25681380 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtype C infection
Number of subjects: 466
Study 25681380 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-B/C subtype infection
Number of subjects: 466
Study 25681417 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting GLS <|9|%
Number of subjects: 202
Study 25681417 — intervention group
Group type: COMPARATOR
Intervention: Resting GLS >|9|%
Number of subjects: 202
Study 25681417 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress GLS <|10|%
Number of subjects: 202
Study 25681417 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress GLS
Number of subjects: 202
Study 25681417 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest GLS
Number of subjects: 202
Study 25681854 — intervention group
Group type: EXPERIMENTAL
Intervention: Second laparoscopic surgery for recurrent unilateral endometriomas (n = 18)
Number of subjects: 36
Study 25681854 — intervention group
Group type: COMPARATOR
Intervention: Control group (no recurrence and no second surgery, n = 18)
Number of subjects: 36
Study 25681854 — intervention group
Group type: EXPERIMENTAL
Intervention: Both study groups (primary surgery)
Number of subjects: 36
Study 25681854 — intervention group
Group type: EXPERIMENTAL
Intervention: Case subjects after second surgery
Number of subjects: 36
Study 25682339 — intervention group
Group type: EXPERIMENTAL
Intervention: Index lesion ablation using high-intensity focused ultrasound
Number of subjects: 56
Study 25682485 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (0.1 mg orally once daily)
Number of subjects: 3
Study 25682595 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyper-CVAD regimen (cyclophosphamide, vincristine, Adriamycin, and dexamethasone) with imatinib
Number of subjects: 54
Study 25682597 — intervention group
Group type: EXPERIMENTAL
Intervention: PR104 (dose ranged from 1.1 to 4 g/m(2))
Number of subjects: 50
Study 25682597 — intervention group
Group type: EXPERIMENTAL
Intervention: PR104 (3 g/m(2) or 4 g/m(2))
Number of subjects: 50
Study 25682597 — intervention group
Group type: EXPERIMENTAL
Intervention: PR104 administration
Number of subjects: 50
Study 25682854 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 289
Study 25682854 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical depressive symptoms
Number of subjects: 289
Study 25682854 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at onset
Number of subjects: 289
Study 25682854 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of suicide attempts
Number of subjects: 289
Study 25682854 — intervention group
Group type: COMPARATOR
Intervention: No rapid cycling
Number of subjects: 289
Study 25683285 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 507
Study 25683846 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.2 mg/kg weekly on days 1, 8, and 15 for two 28-day cycles)
Number of subjects: 45
Study 25683846 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented ICE (augICE) after brentuximab vedotin for PET-positive patients
Number of subjects: 45
Study 25683846 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (brentuximab vedotin followed by augICE)
Number of subjects: 45
Study 25683846 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 45
Study 25684041 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant denosumab
Number of subjects: 0
Study 25684279 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV) administered under medical supervision
Number of subjects: 282
Study 25684279 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 282
Study 25684479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors post cancer directed therapy (CDT)
Number of subjects: 31
Study 25684587 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturation-based media campaigns
Number of subjects: 0
Study 25684587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per disability-adjusted life-year
Number of subjects: 0
Study 25685162 — intervention group
Group type: EXPERIMENTAL
Intervention: Timothy grass sublingual immunotherapy tablet 2800 BAU
Number of subjects: 386
Study 25685352 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Mental Disorders Questionnaire (CMDQ) administered 12 months post-operation and again 14 days later.
Number of subjects: 49
Study 25685352 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Mental Disorders Questionnaire (CMDQ) administered 12 months post-operation.
Number of subjects: 49
Study 25685360 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe
Number of subjects: 1620
Study 25685360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1620
Study 25685703 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-state functional MRI (rs-fMRI) connectivity measures
Number of subjects: 118
Study 25685703 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral measures
Number of subjects: 118
Study 25685703 — intervention group
Group type: COMPARATOR
Intervention: rs-fMRI data
Number of subjects: 118
Study 25685872 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal GFR
Number of subjects: 0
Study 25685872 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced GFR
Number of subjects: 0
Study 25685872 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GFR
Number of subjects: 0
Study 25686166 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP) of 130 to 139 mm Hg
Number of subjects: 3708
Study 25686166 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-updated systolic blood pressure (SBP) of 130 to 139 mm Hg
Number of subjects: 3708
Study 25686166 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP) of 140 mm Hg or greater
Number of subjects: 3708
Study 25686166 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-updated systolic blood pressure (SBP) of 140 mm Hg or greater
Number of subjects: 3708
Study 25686166 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-updated SBP greater than 130 mm Hg
Number of subjects: 3708
Study 25687533 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160mg/d
Number of subjects: 67
Study 25687566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal fluid (CVF) IL-6 ≥463 pg/mL
Number of subjects: 414
Study 25687566 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-marker CVF model (IL-6 + CXCL1 + insulin-like growth factor binding protein-1)
Number of subjects: 414
Study 25687566 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-marker models (IL-6 + CXCL1 or alpha fetoprotein + CXCL1)
Number of subjects: 414
Study 25687566 — intervention group
Group type: EXPERIMENTAL
Intervention: MIAC presence
Number of subjects: 414
Study 25687867 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice a day (days 1 to 21) with cisplatin 80 mg/m(2) (day 1) and capecitabine 1,000 mg/m(2) twice a day (days 1 to 14) in 21-day cycles
Number of subjects: 22
Study 25688511 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 44
Study 25690384 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted grayscale rib series
Number of subjects: 110
Study 25690384 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-modality method (conventional + inverted grayscale rib series)
Number of subjects: 110
Study 25690384 — intervention group
Group type: COMPARATOR
Intervention: Conventional rib series
Number of subjects: 110
Study 25690605 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25690834 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT) using closed-loop fluid administration system with non-invasive cardiac output monitoring (Nexfin™)
Number of subjects: 13
Study 25692527 — intervention group
Group type: EXPERIMENTAL
Intervention: Global coronary artery plaque area
Number of subjects: 108
Study 25692527 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery stenosis ≥50%
Number of subjects: 108
Study 25692527 — intervention group
Group type: COMPARATOR
Intervention: Artery tortuosity
Number of subjects: 108
Study 25692527 — intervention group
Group type: EXPERIMENTAL
Intervention: Global coronary plaque area
Number of subjects: 108
Study 25692692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 7641
Study 25692692 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity statin (atorvastatin ≥40 mg/day or rosuvastatin ≥20 mg/day)
Number of subjects: 7641
Study 25692692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid control
Number of subjects: 7641
Study 25693010 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin
Number of subjects: 130302
Study 25693138 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M SpotOn sensor (zero heat flux method)
Number of subjects: 83
Study 25693419 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAT-up web-based fall-risk assessment tool
Number of subjects: 0
Study 25693610 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthPROMISE app
Number of subjects: 300
Study 25693610 — intervention group
Group type: COMPARATOR
Intervention: Control (patient education app)
Number of subjects: 300
Study 25694653 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy (400/100 mg twice daily)
Number of subjects: 123
Study 25694653 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy with FTC/TDF intensification as needed
Number of subjects: 123
Study 25694653 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy
Number of subjects: 123
Study 25695490 — intervention group
Group type: EXPERIMENTAL
Intervention: Decursin (D) 119 mg
Number of subjects: 20
Study 25695490 — intervention group
Group type: EXPERIMENTAL
Intervention: Decursinol angelate (DA) 77 mg
Number of subjects: 20
Study 25695490 — intervention group
Group type: EXPERIMENTAL
Intervention: Decursinol (DOH) (metabolite)
Number of subjects: 20
Study 25695490 — intervention group
Group type: EXPERIMENTAL
Intervention: Decursin (D)
Number of subjects: 20
Study 25695490 — intervention group
Group type: EXPERIMENTAL
Intervention: Decursinol angelate (DA)
Number of subjects: 20
Study 25695490 — intervention group
Group type: EXPERIMENTAL
Intervention: Decursinol (DOH)
Number of subjects: 20
Study 25696001 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFRvIII-directed CAR T cells
Number of subjects: 0
Study 25696001 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead candidate scFv CAR-transduced T cells
Number of subjects: 0
Study 25696062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior (<100 accelerometry counts/min)
Number of subjects: 1170
Study 25696062 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (100 to 499 accelerometry counts/min)
Number of subjects: 1170
Study 25696062 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (≥500 accelerometry counts/min)
Number of subjects: 1170
Study 25696062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean counts per minute of daily PA
Number of subjects: 1170
Study 25696062 — intervention group
Group type: EXPERIMENTAL
Intervention: Counts per minute of daily PA (sex-specific)
Number of subjects: 1170
Study 25696919 — intervention group
Group type: EXPERIMENTAL
Intervention: Entospletinib (GS-9973) 800 mg twice daily
Number of subjects: 41
Study 25697988 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time, ultrasound-guided infraclavicular axillary vein cannulation
Number of subjects: 29
Study 25698370 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg/week) with methotrexate (6-8 mg/week) for 52 weeks
Number of subjects: 112
Study 25698370 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg/week) with methotrexate (6-8 mg/week)
Number of subjects: 112
Study 25698370 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg/week)
Number of subjects: 112
Study 25698370 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-injection of subcutaneous abatacept
Number of subjects: 112
Study 25698651 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training regimen (30 min per session, 3 times per week for 10 weeks, target heart rate of 70-80% of heart rate reserve)
Number of subjects: 13
Study 25698651 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training regimen
Number of subjects: 13
Study 25698905 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 9468
Study 25698905 — intervention group
Group type: COMPARATOR
Intervention: No statin use
Number of subjects: 9468
Study 25699246 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel brain and vestibular rehabilitation treatment for PTSD
Number of subjects: 98
Study 25699616 — intervention group
Group type: EXPERIMENTAL
Intervention: mobile contingency management (mCM)
Number of subjects: 20
Study 25700037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary cell therapy
Number of subjects: 1252
Study 25700319 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation for coronary patients (C)
Number of subjects: 63
Study 25700319 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation for noncoronary patients (NC)
Number of subjects: 63
Study 25700319 — intervention group
Group type: COMPARATOR
Intervention: Outpatient rehabilitation for both coronary (C) and noncoronary (NC) patients
Number of subjects: 63
Study 25700617 — intervention group
Group type: EXPERIMENTAL
Intervention: iPhone-based remote control system for CT reading
Number of subjects: 120
Study 25700617 — intervention group
Group type: COMPARATOR
Intervention: LCD monitor for CT reading
Number of subjects: 120
Study 25700748 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-RECTOR score for predicting successful guidewire crossing
Number of subjects: 240
Study 25700748 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-RECTOR score
Number of subjects: 240
Study 25700755 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) with a self-expanding bioprosthesis
Number of subjects: 471
Study 25700774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and pemetrexed (DL1: 1250 mg/500 mg)
Number of subjects: 18
Study 25700774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and pemetrexed (DL0: 1250 mg/400 mg)
Number of subjects: 18
Study 25700774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and pemetrexed (DL2: 1500 mg/500 mg)
Number of subjects: 18
Study 25700774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and pemetrexed
Number of subjects: 18
Study 25700893 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 29
Study 25700893 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% milk
Number of subjects: 29
Study 25700893 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 29
Study 25700893 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cola
Number of subjects: 29
Study 25700893 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet cola
Number of subjects: 29
Study 25701004 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ExTr) for 2 months
Number of subjects: 23
Study 25701298 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative accelerated partial breast irradiation (PAPBI) - 40 Gray in 10 fractions over 2 weeks
Number of subjects: 70
Study 25701314 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-HBV-IPV/Hib combination vaccine
Number of subjects: 201
Study 25701453 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, dacarabazine) followed by EB (escalated BEACOPP) for PET-2-positive patients
Number of subjects: 50
Study 25701453 — intervention group
Group type: COMPARATOR
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, dacarabazine) for PET-2-negative patients
Number of subjects: 50
Study 25701453 — intervention group
Group type: EXPERIMENTAL
Intervention: EB (escalated BEACOPP) for PET-2-positive patients
Number of subjects: 50
Study 25702731 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced tobacco abstinence during incarceration
Number of subjects: 262
Study 25703885 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT nonadherence before 6 months
Number of subjects: 2265
Study 25703885 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT nonadherence after 6 months
Number of subjects: 2265
Study 25703885 — intervention group
Group type: COMPARATOR
Intervention: Major bleeding
Number of subjects: 2265
Study 25703885 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT nonadherence within 6 months
Number of subjects: 2265
Study 25704212 — intervention group
Group type: COMPARATOR
Intervention: Pattern II subjects during arm lowering
Number of subjects: 82
Study 25704212 — intervention group
Group type: COMPARATOR
Intervention: Mixed pattern I and II subjects during arm lowering
Number of subjects: 82
Study 25704212 — intervention group
Group type: COMPARATOR
Intervention: Pattern I subjects during arm lowering
Number of subjects: 82
Study 25704439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) administered intravenously every 2 weeks until progression or unacceptable toxic effects
Number of subjects: 117
Study 25706232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily for 12 weeks
Number of subjects: 50
Study 25707037 — intervention group
Group type: EXPERIMENTAL
Intervention: Automessages encouraging group discussion on cessation-related topics and individualized autofeedback.
Number of subjects: 40
Study 25707037 — intervention group
Group type: EXPERIMENTAL
Intervention: Automessages
Number of subjects: 40
Study 25707037 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific tweet content (setting quit date, use of nicotine patches)
Number of subjects: 40
Study 25707037 — intervention group
Group type: EXPERIMENTAL
Intervention: Countering roadblocks to quitting
Number of subjects: 40
Study 25707037 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressions of confidence about quitting
Number of subjects: 40
Study 25707037 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-evidence-based information about quitting
Number of subjects: 40
Study 25708759 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted underwater en bloc resection (UEBR) using a 33-mm snare
Number of subjects: 50
Study 25708759 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted underwater en bloc resection (UEBR)
Number of subjects: 50
Study 25708759 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up colonoscopy after UEBR
Number of subjects: 50
Study 25709506 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (standard protocol)
Number of subjects: 11
Study 25709506 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (GnRH antagonist initiated on day 10)
Number of subjects: 11
Study 25709506 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C (GnRH antagonist initiated on day 20)
Number of subjects: 11
Study 25709506 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols B and C (GnRH antagonist protocols)
Number of subjects: 11
Study 25710027 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 10
Study 25710027 — intervention group
Group type: COMPARATOR
Intervention: Very low calorie diet
Number of subjects: 10
Study 25710187 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis using [(123)I]FP-CIT SPECT images with support vector machines
Number of subjects: 654
Study 25710187 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 654
Study 25710456 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of panobinostat (30 mg) and carfilzomib (20/45 mg/m²)
Number of subjects: 44
Study 25710456 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of panobinostat and carfilzomib
Number of subjects: 44